Regulatory News:

BIOCORP (Paris:ALCOR) (ISIN: FR0012788065; Mnemo: ALCOR), a French company specializing in the development and manufacturing of innovative medical and drug delivery devices, announces today its financial reporting schedule for 2016.

Publication   Date*
2015 full-year results  

Thursday, April 7, 2016
before the market opening

Annual shareholders meeting   Thursday, May 12, 2016
2016 first-half year results  

Thursday, September 29, 2016
after the market close

* This schedule is indicative and subject to change.

ABOUT BIOCORP

Founded in 2004 in Issoire (near Clermont-Ferrand, France), Biocorp is a French company specializing in the development and manufacturing of medical devices and innovative drug delivery systems. It is listed as ‘Innovative Company’ by the French public investment bank Bpifrance. With over twenty years of experience and more than 30 manufactured products, Biocorp is a key player in the industry, providing drug delivery solutions that meet the evolving needs of patients. Today, Biocorp continues to innovate in the area of medical plastics, its core business, and to market traditional devices (alternative to aluminum capsules, syringe and vial administration systems) that have been an important source of recurring income. Its solid expertise and capacity to innovate have allowed the company to develop new internet-connected products, including: the DataPen, a reusable smart injection pen that automatically transmits data to a mobile app, helping patients to manage their treatment; and treatment management add-ons, which adapt to existing delivery devices and are compatible with most injection pens in the market. The company has a team of 43 employees. Biocorp is listed on Alternext since July 2015 (FR12788065 – ALCOR).

For more information, please visit: www.biocorp.fr - Follow us on Twitter @BIOCORPSystems